Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2016-03-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Rituximab-induced-neutropenia-in-a-patient-with-inflammatory-myopathy-and-systemic-sclerosis-overlap-disease,18,27173,1,1.html |
| Summary: | Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease.We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients. |
|---|---|
| ISSN: | 0034-6233 2084-9834 |